Aytu BioPharma (AYTU) announced the commercial availability of EXXUA in the United States. EXXUA is the first and only 5HT1a agonist approved by the United States Food and Drug Administration for the treatment of major depressive disorder, representing a new way to treat MDD. The immediate availability of EXXUA through participating Aytu RxConnect pharmacies enables patients and prescribers the ability to access EXXUA through Aytu’s best-in-class patient access program, Aytu RxConnect. In parallel, distribution through all major United States wholesalers is progressing to enable nationwide availability across all pharmacy retailers in the coming weeks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU:
- Aytu BioScience Stockholders Approve Key Proposals
- Aytu BioScience Earnings Call Highlights Growth and Challenges
- Aytu BioScience: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Aytu BioPharma Reports Q1 2026 Earnings and EXXUA Launch Plans
- Aytu BioScience (AYTU) Q1 Earnings Cheat Sheet